Compare Stocks: BBIO vs. CORT vs. AXSM vs. SMMT

Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
BBIOCORTAXSMSMMT
+20.01%+245.93%+18.89%-18.21%

Market Snapshot

Current market context for the selected companies.

Performance

Absolute returns and relative performance versus SPY.

Metric BBIOCORTAXSMSMMT
1 Month-1.7%+26.5%-14.0%-12.1%
1 Month vs SPY-5.5%+22.7%-17.7%-15.9%
3 Months+16.0%+104.8%-11.1%-24.7%
3 Months vs SPY+12.9%+101.7%-14.2%-27.8%
6 Months+19.6%+251.1%+13.1%-17.4%
6 Months vs SPY+8.5%+240.0%+2.0%-28.5%
1 Year+66.7%+73.7%+77.6%-49.1%
1 Year vs SPY+46.7%+53.7%+57.6%-69.1%
2 Years+234.0%+259.9%+141.1%+13.4%
2 Years vs SPY+195.9%+221.7%+103.0%-24.7%

Growth & Profitability

Operating growth, margins and capital efficiency.

Metric BBIOCORTAXSMSMMT
Revenue Growth120.4%31.7%45.5%
Earnings Growth24.1%
Gross Margin94.4%98.3%93.2%0.0%
Operating Margin-43.9%16.1%-23.4%0.0%
Net Margin-97.0%6.6%-24.7%0.0%
Return on Equity8.2%-245.1%-192.5%
Return on Assets-26.0%0.5%-16.3%-101.6%

Valuation

Common valuation multiples shown side by side.

Metric BBIOCORTAXSMSMMT
P / E269.0
Forward P / E532.127.841.3-10.8
P / S22.715.814.0
P / B-6.418.5130.615.7
EV / Sales26.715.413.9
EV / EBIT-60.995.5-59.4-40.9
P / FCF-50.6169.1-2,378.3-71.0
FCF Yield-2.0%0.6%-0.0%-1.4%

Cash Flow & Balance Sheet

Cash generation and leverage context.

Metric BBIOCORTAXSMSMMT
Free Cash Flow-$320.26M$77.40M-$4.58M-$139.68M
Operating Cash Flow-$434.37M$109.70M-$71.26M-$458.43M
Debt / Equity1.3%269.7%3.2%

Earnings Outlook

Upcoming earnings expectations when available.

Metric BBIOCORTAXSMSMMT
Next Earnings2026-10-282026-11-022026-10-19
EPS Estimate-0.58-0.78-0.22
Revenue Estimate219.71M221.78M53.64k
EPS Growth+38.7%+19.5%+6.9%
Revenue Growth+98.7%+47.8%+0.0%
Analyst Coverage71112